2020 年第 5 期 第 15 卷

丁苯酞联合依达拉奉对高血压脑出血患者脑血管功能及降钙素基因相关肽和沉默信息调节因子1水平的影响

Effect of butylphthalide combined with edaravone on cerebrovascular function, calcitonin gene related peptide and silent information regulator 1 in patients with hypertensive cerebral hemorrhage

作者：刘杨1;吴功祥1;杨静2

英文作者：Liu Yang1 Wu Gongxiang1 Yang Jing2

单位：1安徽省第二人民医院老年科，合肥230031；2安徽省第二人民医院慢性病科，合肥230031

英文单位：1Department of Geriatrics Anhui No.2 Provincial People′s Hospital Hefei 230031 China; 2Department of Chronic Diseases Anhui No.2 Provincial People′s Hospital Hefei 230031 China

关键词：高血压脑出血；丁苯酞；依达拉奉；脑血管功能；血管内皮细胞功能；降钙素基因相关肽；沉默信息调节因子

英文关键词：Hypertensivecerebralhemorrhage；Butylphthalide；Edaravone；Cerebrovascularfunction；Vascularendothelialcellfunction；Calcitoningenerelatedpeptide；Silenceinformationregulator

• 摘要：

• 目的 探究丁苯酞联合依达拉奉对高血压脑出血（HCH）患者脑血管功能及降钙素基因相关肽（CGRP）、沉默信息调节因子 1（SIRT1）水平的影响。方法 选取安徽省第二人民医院2017年6月至2019年6月收治的100例HCH患者，按奇偶数法随机分为观察组（50例）和对照组（50例）。2组均予以常规对症治疗，并予以依达拉奉静脉滴注，观察组加服丁苯酞软胶囊，均连续治疗28 d。观察2组治疗后的临床疗效，比较2组治疗前后的脑血管功能指标、血管内皮细胞功能指标及CGRP、SIRT1水平。结果 观察组总有效率明显高于对照组［94.0%（47/50）比78.0%（39/50）］，差异有统计学意义（P=0.021）。2组治疗后脑血管平均流速、平均流量、一氧化氮水平均明显高于治疗前，且观察组明显高于对照组，脑血管周围阻力、动态阻力、氧化型低密度脂蛋白胆固醇、内皮素1、细胞间黏附分子1、血管细胞黏附分子1、血小板衍生因子、肿瘤坏死因子α、白细胞介素6、CGRP和SIRT1水平均明显低于治疗前，且观察组明显低于对照组，差异均有统计学意义（均P＜0.05）。结论丁苯酞联合依达拉奉可显著改善HCH患者脑血管功能和血管内皮细胞功能，降低CGRP和SIRT1水平，临床疗效显著。

• Objective To investigate the effect of butylphthalide combined with edaravone on cerebrovascular function, calcitonin gene-related peptide (CGRP) and silent information regulator 1(SIRT1) in patients with hypertensive cerebral hemorrhage (HCH). Methods Totally 100 patients with HCH admitted in Anhui No.2 Provincial People′s Hospital from June 2017 to June 2019 were randomly divided into the observation group (50 cases) and the control group (50 cases). Both groups were given conventional symptomatic treatment and edaravone intravenous drip; the observation group was additionally given butylphthalide soft capsule. Both groups received continuous treatment for 28 days. The clinical data were observed, including the cerebrovascular function indexes, vascular endothelial cell function indexes, CGRP and SIRT1. Results The total clinical effective rate in observation group was higher than that in control group［94.0%（47/50） vs 78.0%（39/50）, P=0.021］. After treatment, the average cerebrovascular flow rate, average flow rate and nitric oxide level in the two groups were higher than those before treatment, and these indicators of the observation group were significantly higher than the control group.Cerebrovascular peripheral resistance, dynamic resistance, oxidized low density lipoprotein cholesterol, endothelin 1, intercellular adhesion molecule 1, vascular cell adhesion molecule 1, platelet derived factor, tumor necrosis factor α, interleukin 6, CGRP and SIRT1 levels were lower than those before treatment, and these indicators of the observation group were significantly higher than the control group (P＜0.05). ConclusionButylphthalide combined with edaravone can significantly improve cerebral vascular function and vascular endothelial cell function in patients with HCH; it can reduce CGRP and SIRT1 levels.